COVID-19-Associated Mucormycosis in Diabetic Patients: The Tip of an Iceberg
,
Abstract
No Abstract
1. Forouzesh M, Farshid S, Ghiasi N, et al (2021). Mucormycosis (black fungus/zygomycosis) and COVID-19; Does the coexistence of these two increase mortality?
2. Segrelles-Calvo G, de S Araújo GR, Frases S(2020). Systemic mycoses: a potential alert for complications in COVID-19 patients. Future Microbiol. 15:1405-1413.
3. Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R (2021). Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World. Mycopathologia, 186(6):739-754.
4. Gupta KL, Gupta A (2012). Mucormycosis and acute kidney injury. J Nephropathol,1(3):155-159.
5. Scott ES, Jenkins A, Fulcher GR (2020). Challenges of diabetes management during the COVID-19 pandemic. Med J Aust, 213(2):56-7.
6. Valizadeh R, Dadashzadeh N, Zakeri R, et al (2020). Drug therapy in hospitalized patients with very severe symptoms following COVID-19. J Nephropharmacol,9(2):e21.
7. Pakdel F, Ahmadikia K, Salehi M, et al (2021). Mucormycosis in patients with COVID‐19: a cross‐sectional descriptive multicentre study from Iran. Mycoses, 64(10):1238-52.
8. Singh AK, Singh R, Joshi SR, Misra A (2021). Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr,15(4):102146.
9. Maartens G, Wood MJ (1991). The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother, 28 Suppl A :13-22.
10. Pal R, Bhadada SK, Misra A (2021). COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab Syndr,15(2):505-508.
2. Segrelles-Calvo G, de S Araújo GR, Frases S(2020). Systemic mycoses: a potential alert for complications in COVID-19 patients. Future Microbiol. 15:1405-1413.
3. Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R (2021). Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World. Mycopathologia, 186(6):739-754.
4. Gupta KL, Gupta A (2012). Mucormycosis and acute kidney injury. J Nephropathol,1(3):155-159.
5. Scott ES, Jenkins A, Fulcher GR (2020). Challenges of diabetes management during the COVID-19 pandemic. Med J Aust, 213(2):56-7.
6. Valizadeh R, Dadashzadeh N, Zakeri R, et al (2020). Drug therapy in hospitalized patients with very severe symptoms following COVID-19. J Nephropharmacol,9(2):e21.
7. Pakdel F, Ahmadikia K, Salehi M, et al (2021). Mucormycosis in patients with COVID‐19: a cross‐sectional descriptive multicentre study from Iran. Mycoses, 64(10):1238-52.
8. Singh AK, Singh R, Joshi SR, Misra A (2021). Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr,15(4):102146.
9. Maartens G, Wood MJ (1991). The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother, 28 Suppl A :13-22.
10. Pal R, Bhadada SK, Misra A (2021). COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab Syndr,15(2):505-508.
| Files | ||
| Issue | Vol 51 No 2 (2022) | |
| Section | Letter to the Editor | |
| DOI | https://doi.org/10.18502/ijph.v51i2.8704 | |
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Parsaei A, Mohammadi Kooshki A, Nasri H, Hassanzadeh S. COVID-19-Associated Mucormycosis in Diabetic Patients: The Tip of an Iceberg. Iran J Public Health. 2022;51(2):473-475.
